MedTrace Logo

Cabazitaxel in Platinum Refractory Ovarian Cancer

NCT01747239 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2014-12-04

No results posted yet for this study

Summary

Ovarian cancer patients are considered platinum refractory if their disease worsens during primary platinum treatment or if they have no effect of the treatment. This constitutes a major therapeutic problem and new treatment approaches are highly needed.

Cabazitaxel (Jevtana®) is a new taxane with effect in breast and prostatic cancer. In both tumors it has effect in patients refractory to taxotere. Consequently, it could be anticipated that cabazitaxel may have an effect in platinum refractory ovarian cancer.

Conditions

Interventions

DRUG

Cabazitaxel

25 mg/m2 IV every three weeks

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Anders Jakobsen, DMSc · Vejle Hospital

  • Christine V Madsen, MD · Vejle Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01747239 on ClinicalTrials.gov